Oscar Health (NYSE:OSCR) Sets New 12-Month High – What’s Next?

by · The Markets Daily

Oscar Health, Inc. (NYSE:OSCR – Get Free Report)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $33.10 and last traded at $32.1050, with a volume of 22014 shares traded. The stock had previously closed at $32.18.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Zacks Research downgraded Oscar Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 5th. Robert W. Baird lifted their target price on Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Wolfe Research initiated coverage on Oscar Health in a research note on Tuesday, May 5th. They set a “peer perform” rating for the company. Wall Street Zen raised shares of Oscar Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 14th. Finally, Barclays upgraded shares of Oscar Health from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $30.00 to $35.00 in a research note on Wednesday, June 10th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.78.

View Our Latest Research Report on Oscar Health

Oscar Health Price Performance

The firm has a market cap of $9.65 billion, a P/E ratio of -54.09, a price-to-earnings-growth ratio of 2.25 and a beta of 2.34. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26. The business has a 50-day moving average of $24.49 and a two-hundred day moving average of $17.88.

Oscar Health (NYSE:OSCR – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.90 billion. During the same quarter in the prior year, the firm earned $0.92 EPS. The business’s revenue for the quarter was up 52.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Oscar Health, Inc. will post 0.47 earnings per share for the current fiscal year.

Insider Transactions at Oscar Health

In other Oscar Health news, CEO Mark T. Bertolini sold 624,244 shares of Oscar Health stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $28.48, for a total value of $17,778,469.12. Following the completion of the sale, the chief executive officer directly owned 7,751,570 shares of the company’s stock, valued at approximately $220,764,713.60. The trade was a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mario Schlosser sold 147,500 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $29.38, for a total transaction of $4,333,550.00. Following the transaction, the director owned 1,360,866 shares in the company, valued at $39,982,243.08. This represents a 9.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 3,662,466 shares of company stock valued at $105,145,815. 25.11% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OSCR. Vanguard Group Inc. grew its stake in Oscar Health by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock valued at $297,477,000 after acquiring an additional 540,851 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Oscar Health by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 4,798,313 shares of the company’s stock worth $68,964,000 after purchasing an additional 116,430 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Oscar Health by 1,097.8% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 237,882 shares of the company’s stock worth $3,418,000 after purchasing an additional 218,022 shares in the last quarter. BIT Capital GmbH grew its position in Oscar Health by 545.0% in the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock valued at $88,897,000 after purchasing an additional 5,227,152 shares during the period. Finally, Farallon Capital Management LLC increased its stake in Oscar Health by 146.5% during the 3rd quarter. Farallon Capital Management LLC now owns 3,639,000 shares of the company’s stock valued at $68,886,000 after purchasing an additional 2,163,000 shares in the last quarter. 75.70% of the stock is owned by institutional investors and hedge funds.

About Oscar Health

(Get Free Report)

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

Further Reading